1425-10-1

Usage

Uses

Used in Veterinary Medicine:
19-NORTESTOSTERONE ACETATE is used as a performance-enhancing drug for improving muscle growth and athletic performance in animals.
Used in Clinical Settings:
19-NORTESTOSTERONE ACETATE is used as a therapeutic agent for promoting muscle growth and enhancing athletic performance in humans, particularly in conditions where muscle wasting or weakness is a concern.
Used in Sports Performance Enhancement:
19-NORTESTOSTERONE ACETATE is used as an ergogenic aid for increasing muscle mass, strength, and endurance in athletes, although its use is often prohibited in competitive sports due to potential health risks and ethical concerns.
Used in Treatment of Anemia:
19-NORTESTOSTERONE ACETATE is used as a medication for treating anemia, particularly in cases where increased red blood cell production is required.
Used in Bone Health:
19-NORTESTOSTERONE ACETATE is used as a treatment for improving bone density in conditions such as osteoporosis, where bone strength and integrity are compromised.
Used in Appetite Stimulation:
19-NORTESTOSTERONE ACETATE is used as an appetite stimulant for individuals with conditions that result in poor appetite or weight loss, such as cachexia or anorexia.

Upstream product

• 434-22-0 19-nortestosterone 
• 108-24-7 acetic anhydride 
• 2590-41-2 6-dehydro-19-nortestosterone acetate 
• 762-72-1 allyl-trimethyl-silane 
• 7082-72-6 3,19-Dioxo-17β-acetoxy-Δ⁴-androsten 
• 4999-76-2 3,17β-diacetoxyoestra-3,5-diene 
• 1091-93-6 3-methoxy-17-hydroxyestra-2,5⁽¹⁰⁾-diene 
• 6678-08-6 17β,19-dihydroxyandrost-4-en-3-one 17-acetate 
• 1758-20-9 17β,19-dihydroxy-androst-4-en-3-one 17,19-diacetate 

Downstream Products

• 1164-99-4 17β-acetoxy-4-chloro-estr-4-en-3-one 
• 6197-94-0 17β-acetoxy-5-oxo-3,5-seco-A-nor-estran-3-oic acid 
• 33767-87-2 17β-acetoxy-5α-estran-3-one 
• 2302-77-4 17β-acetoxy-5β-estran-3-one 
• 1743-60-8 17-β-estradiol 17-acetate 
• 18367-54-9 3,3-(ethylenedioxy)-5(10)-estren-17β-yl acetate 
• 362-05-0 2-Hydroxyestradiol 
• 23463-05-0 estra-1,3,5(10)-triene-2,3,17β-triol-17-acetate 
• 474-86-2 equilin 
• 14531-84-1 17β-hydroxyestra-4,6-dien-3-one 
• 13209-45-5 estra-4,6-diene-3,17-dione 
• 2590-41-2 6-dehydro-19-nortestosterone acetate 
• 2302-77-4 17β-Acetoxy-3-oxo-19-nor-androstan 
• 1092-04-2 2α-Methyl-19-nor-testosteron 

Relevant academic research and scientific papers

NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I) : and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein-, R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF

Provided herein are 3,3-disubstituted19-nor-steroidal compounds according to Formula(I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions,for example, treatment of sleep disorders, mood disorders,schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders,personality disorders,autism spectrum disorders, pain,traumatic brain injury, vascular diseases,substance abuse disorders and/or withdrawal syndromes, tinnitus, status epilepticus.

The Preparation of 7α- and 7β-Allyloestradiol, and an Unusual Titanium(IV) Chloride Mediated Dimerisation

17β-Acetoxyoestra-4,6-dien-3-one reacts with allyltrimethylsilane in the presence of fluoride ion to give the 7α- and 7β-allyloestr-4-en-3-ones in low yield.With titanium(IV) chloride catalysis, the 7α-allyloestr-4-en-3-one is the only product at -78 deg C, but its novel 6β,6'β-'dimer' is also formed at higher temperatures.The isomeric 7-allyloestr-4-en-3-ones have been aromatised to give 7α- and 7β-allyloestradiols.

Synthesis of gon-4-enes

1. A therapeutic composition having progestational activity comprising as active ingredient a 17-aliphatic carboxylic acid ester of 17α-ethynyl-18-methyl-19-nortestosterone and a pharmaceutical carrier for said compound.

Synthesis of 13-alkyl-gon-4-ones

The preparation of 13-methylgon-4-enes and novel 13-polycarbonalkylgon-4-enes by a new total synthesis is described. 13-Alkylgon-4-enes having progestational, anabolic and androgenic activities are prepared by forming a tetracylic gonane structure unsaturated in the 1,3,5(10),9(11) and 14-positions, selectively reducing in the B- and C-rings, and converting the aromatic A-ring compounds so-produced to gon-4-enes by Birch reduction and hydrolysis.

Steroidal imidazole 1 carboxylic acid esters

A variety of steroidal esters of imidazole 1 carboxylic acid and related acids was prepared by reaction of the steroidal alcohol with N,N' carbonyldiimidazole or by displacement of phenol from steroid phenylcarbonates. One compound, 21c (the imidazole 1 carboxylate of 19 norethisterone), was found to have an interesting separation of progestational from androgenic activity.